$1.4B Zyprexa Deal Could Spark More Qui Tam Suits

Law360, New York (January 15, 2009, 12:00 AM EST) -- Eli Lilly & Co.'s record-breaking $1.4 billion deal to settle charges that it illegally marketed its anti-psychotic treatment Zyprexa for off-label use could stimulate, one observer says, a wave of false as well as legitimate whistleblower complaints.

The Indiana-based pharmaceutical giant's agreement with the U.S. Attorney's Office for the Eastern District of Pennsylvania and 30 states, announced Thursday, is believed to be the largest-ever health care fraud settlement and resolves four qui tam cases that were consolidated in the U.S. District Court for the Eastern District...
To view the full article, register now.